BRCA1 and breast cancer: Compared with high-risk BC surveillance and tamoxifen from age 30 years, RRM (at age 30 years), RRSO (at age 35 years), or undergoing both RRM (at 30 years) and RRSO (at 35 years) were cost-effective or cost-saving for BRCA1 PV carriers.